By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Meridian Bioscience today provided guidance for its 2012 fiscal year, projecting net income to improve between 20 and 30 percent above projected fiscal 2011 income on the strength of its illumigene franchise.

For the year ending Sept. 30, 2012, the company expects EPS to fall between $.85 and $.89 on net sales of between $183 million and $192 million. The guidance excludes reorganization costs in 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.